Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Fenofibrate, PPARα–YAP Signaling, and Liver Aging
2026-09-19
The reference study shows that fenofibrate-induced liver enlargement and activation of the PPARα–YAP signaling axis are preserved across multiple aging mouse models. Its findings suggest that aging does not substantially eliminate this hepatic response, while also defining useful experimental endpoints for lipid metabolism research and studies of liver growth.
-
Acifran Workflows for HCAR2/HCAR3 Research
2026-09-18
Acifran enables controlled HCAR2/GPR109A and HCAR3/GPR109B agonism for cAMP, receptor pharmacology, and lipid metabolism workflows. Structure-guided pairing of receptor assays with careful compound handling helps distinguish ligand response from solubility, expression, and assay-window artifacts.
-
Protein A/G Magnetic Co-IP/IP Kit for IVDD
2026-09-18
Learn how the Protein A/G Magnetic Co-IP/IP Kit can translate BATF2-ATF3 findings into rigorous protein-complex experiments in intervertebral disc degeneration. This guide connects magnetic immunoprecipitation design with mitochondrial biology, controls, workflow choices, and interpretation limits.
-
LY2886721: From BACE1 Potency to Assay Design
2026-09-17
LY2886721 is a BACE inhibitor suited to mechanistic Alzheimer’s disease research. This article explains how to connect biochemical potency, APP-processing biomarkers, amyloid beta reduction, and synaptic readouts into a better experimental design.
-
TCAIM–OGDH Control of Mitochondrial Metabolism
2026-09-17
The 2025 Molecular Cell study identifies TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds native OGDH and lowers its abundance through an HSPA9- and LONP1-dependent process. The findings establish mitochondrial proteostasis as an active regulator of metabolic enzyme levels, OGDH complex activity, and carbohydrate catabolism in cells and mice.
-
Berberrubine chloride Research Workflows
2026-09-16
Build mechanism-led workflows around Berberrubine chloride for colorectal cancer, NSCLC chemosensitivity, hyperuricemia, and enzyme-mediated drug-interaction studies. The platform combines DMSO-compatible formulation, multi-target biology, and a newly defined mechanism-based CYP2D6 inactivation workflow.
-
Ampicillin sodium for Selection and Assay Workflows
2026-09-16
Ampicillin sodium supports two complementary research needs: plasmid selection during recombinant protein production and controlled β-lactam exposure in antibacterial activity assays. This guide connects those use cases with a reference-based annexin V workflow, practical protocol parameters, and troubleshooting strategies for reproducible results.
-
FITC-Concanavalin A (ConA) Conjugate Guide
2026-09-15
FITC-Concanavalin A (ConA) Conjugate is a fluorescent lectin reagent for detecting α-D-glucose and α-D-mannose residues on glycoproteins and glycolipids in cell or tissue samples. It supports immunofluorescence staining and flow cytometry carbohydrate analysis, but it should not be treated as a general glycan stain, an antibody substitute, or a probe for non-carbohydrate targets.
-
FLOT1–FOSL2–EphA2 Axis in AD Neuroinflammation
2026-09-15
A 2026 Neuropharmacology study identifies a FLOT1–FOSL2–EphA2 regulatory axis that promotes pro-inflammatory microglial polarization through p38/MAPK signaling in an APP/PS1 model. By combining molecular interaction assays with behavioral testing, the work connects a defined transcriptional mechanism to neuroinflammation and impaired spatial memory, while also clarifying how the pathway might be examined in complementary cell-based systems.
-
BCA Protein Quantification Kit K4102 Guide
2026-09-14
The Bicinchoninic Acid Assay (BCA) Protein Quantification Kit K4102 supports total-protein measurement in dilute samples, including many detergent-containing preparations and cell lysates. It is intended for scientific research workflows such as sample normalization and is not for diagnostic, clinical, or medical testing.
-
BCA Protein Quantification Kit: K4102 Guide
2026-09-14
The Bicinchoninic Acid Assay (BCA) Protein Quantification Kit K4102 supports sensitive total-protein measurement in dilute samples, including many detergent-containing preparations and cell lysates. It is intended for scientific research workflows such as sample normalization and is not validated for diagnostic, clinical, or medical use.
-
Açaí Extracts in Human Hepatocytes: Key Findings
2026-09-13
Raichura and colleagues combined cytotoxicity testing, hepatocyte gene-expression analysis, and complementary transporter assays to evaluate whether consumer-relevant açaí extracts alter pharmacokinetic pathways. The study found extract-specific, dose- and time-dependent loss of hepatocyte viability but little evidence of CYP or transporter induction, supporting more disciplined evaluation of botanical–drug interaction risk.
-
(R)-MG132: A Rigorous Proteasome Negative Control
2026-09-12
(R)-MG132 is an MG-132 enantiomer with markedly reduced 20S proteasome chymotrypsin-like inhibition. Its functionally inactive profile supports proteasome inhibition validation, cell-based assay proteasome control, and mechanistic studies that separate on-target effects from nonspecific toxicity.
-
Potassium Iodide in Thyroid Assay Design
2026-09-11
Potassium Iodide (KI) gives researchers a defined iodide variable for thyroid uptake, hormone-synthesis, and radioactive iodine competition assays. This guide turns a soluble research reagent into a controlled workflow, then connects its assay-design logic with responsive delivery principles from combination immunotherapy.
-
Partial BACE Inhibition and Synaptic Transmission
2026-09-11
Satir et al. examined whether moderate β-secretase inhibition can lower amyloid beta secretion without disrupting neuronal communication. Using primary rat cortical cultures, optical electrophysiology, and three BACE inhibitors, the study found that reductions below 50% were not associated with impaired synaptic transmission, whereas stronger inhibition decreased both amyloid beta secretion and synaptic activity.